Gilead wins label expansion for Vemlidy to treat hepatitis B virus in kids
Gilead Sciences’ Vemlidy on Thursday secured a label expansion from the FDA, allowing the antiviral drug’s use to treat chronic hepatitis B in pediatric patients aged six years and older.